The Use of Low Ammonia Concentration in the Radiochemical Purity Test of [153Sm]Sm-EDTMP by Using the Thin Layer Chromatography Method
Amal Rezka Putra, Khoirunnisa Fauziah Asyikin, Robertus Dwi Hendarto, Agus Ariyanto, Enny Lestari, Sumandi Juliyanto, Ahsanal Fikri
J. Pure App. Chem. Res. Vol 10, No 1 (2021), pp. 37-43
Submitted: August 30, 2020     Accepted: April 14, 2021     Published: April 14, 2021


Cover Image

Radiochemical purity testing of [153Sm]Sm-EDTMP usually uses the Thin Layer Chromatography method. The mobile phase used is a mixture of 25% ammonia and water. However, the lowest ratio of 25% ammonia in the mobile phase is unknown. Therefore, research related to the use of the lowest concentration in the radiochemical purity test of [153Sm]Sm-EDTMP is necessary. This research method includes labelling of EDTMP using Samarium-153, preparation of the mobile phase with variations in the concentration of 25% ammonia: water, radiochemical purity test and data analysis using t-test statistics. The results of this study are the concentration of 25% ammonia: water (1: 9) to (1: 200) still shows good separation with Rf of [153Sm]SmCl3 and [153Sm]Sm-EDTMP at 0.0, 1.0 respectively, whereas with a thinner concentration of ammonia indicates less optimal separation with Rf [153Sm]SmCl3 at 0.35 to 1.0. Comparison of concentrated ammonia concentrations of 1: 9 and dilute 1: 200 was performed using a statistical t-test. The results of the data analysis showed that the two methods were not significantly different, indicated by the t-value of 0.82 less than 2.78. The conclusion of this study is that the lowest concentration of 25% ammonia and water in the radiochemical purity test of [153Sm]Sm-EDTMP is 1: 200.

Keywords : Radiochemical purity; [153Sm]Sm-EDTMP; Thin Layer Chromatography; Ammonia Concentration; Mobile phase
Full Text: PDF


[1] Coenen, H.H., Gee, A.D., Adam, M., Antoni, G., Cutler, C.S., Fujibayashi, Y., Jeong, J.M., Mach, R.H., Mindt, T.L., Pike, V.W., and Windhorst, A.D., Nucl. Med. Biol., 2017, 55, v–xi.

[2] U.S. Pharmacopoeia 29th edition online version, United States, Monographs, 2006,

[3] Anderson, P.M., Subbiah, V., and Rohren, E. Current Advances in Osteosarcoma, 2014, 804, 291–304.

[4] Vigna, L., Matheoud, R., Ridone, S., Arginelli, D., Della Monica, P., Rudoni, M., Inglese, E., and Brambilla, M., Phys. Medica, 2011, 27(3), 144–152.

[5] Fallahpoor, M., Abbasi, M., Asghar Parach, A., and Kalantari, F., Appl. Radiat. Isot., 2017, 124, 1–6.

[6] Ranjbar, H., Ghannadi-Maragheh, M., Bahrami-Samani, A., and Beiki, D. Radiat. Phys. Chem, 2015, 108, 60–64.

[7] Sardari, D., and Hakimi, A. Reports Pract. Oncol. Radiother. 2012, 17(6), 358–362.

[8] Edam, A.N., Sulieman, A., Sam, A.K., Salih, I., Alkhorayef, M., and Bradley, D.A. Radiat. Phys. Chem., 2020, 167, 108247.

[9] Taylor, A.T., J. Nucl. Med., 2014, 55(4), 608–615.

[10] IAEA TECDOC SERIES – 1856, Quality Control in the Production of Radiopharmaceuticals, 2018, pp. 124–126,

[11] Vallabhajosula, S., Killeen, R.P., and Osborne, J.R. Semin. Nucl. Med., 2010, 40(4), 220–241.

[12] Gómez-Perales, J. L., López-Martínez, E., and García-Mendoza, A. Appl. Radiat. Isot., 2016, 118, 102–104.

[13] Kadarisman, Hastini, S., Tahyan, Y., Abidin, Hafid, D., and Lestari, E. J. Radioisot. Radiopharm., 2006, 9, 13–22.

[14] International Pharmacopoeia 9th edition online version, United States,.Monographs Radiopharmaceuticals Specific monographs, 2019.

[15] Solga, S.F., Mudalel, M., Spacek, L.A., Lewicki, R., Tittel, F., Loccioni, C., Russo, A., and Risby, T.H., J. Breath Res., 2013, 7, 037101.

[16] West, C., Melin, J., Ansouri, H., and Mengue Metogo, M., J. Chromatogr. A., 2017, 1492, 136–143.

[17] Shewiyo, D.H., Kaale, E., Risha, P.G., Dejaegher, B., Smeyers-Verbeke, J., and Vander Heyden, Y., J. Chromatogr. A., 2012, 1260, 232–238.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.